Dehydroepiandrosterone ( DrugBank: Dehydroepiandrosterone )

---

5 diseases

ID	Disease name (Link within this page)	Number of trials
49	Systemic lupus erythematosus	5
53	Sjogren syndrome	3
83	Addison disease	1
96	Crohn disease	1
113	Muscular dystrophy	1

49. Systemic lupus erythematosus

---

Clinical trials : 993 /  Drugs : 702 - (DrugBank : 184) / Drug target genes : 116 - Drug target pathways : 200

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00189124 (ClinicalTrials.gov)	September 2003	13/9/2005	Dehydroepiandrosterone (DHEA) in Systemic Lupus Erythematosus (SLE) for Coronary Artery Disease (CAD) Prevention	Does DHEA Improve Endothelial Dysfunction and Other Cardiovascular Risk Factors in Premenopausal Women With Systemic Lupus?	Systemic Lupus Erythematosus	Drug: Dehydroepiandrosterone (DHEA)	University of Michigan	Arthritis Foundation	Completed	18 Years	N/A	Female	13	Phase 2/Phase 3	United States
2	NCT00391924 (ClinicalTrials.gov)	May 2000	24/10/2006	Dehydroepiandrosterone Administration in Women With Systemic Lupus Erythematosus or Primary Sjögren's Syndrome	Fatigue and General Well-Being in Patients With Systemic Lupus Erythematosus or Primary Sjögren's Syndrome: Effects of Dehydroepiandrosterone Administration	Lupus Erythematosus, Systemic;Sjogren's Syndrome	Drug: Dehydroepiandrosterone	UMC Utrecht	University Medical Centre Groningen;Dutch Arthritis Association	Completed	18 Years	N/A	Female	120	Phase 2	Netherlands
3	NCT00004662 (ClinicalTrials.gov)	March 1996	24/2/2000	Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone in Women With Active Systemic Lupus Erythematosus		Systemic Lupus Erythematosus	Drug: dehydroepiandrosterone	National Center for Research Resources (NCRR)	Northwestern University	Completed	18 Years	N/A	Female	300	Phase 3	NULL
4	NCT00004665 (ClinicalTrials.gov)	June 1995	24/2/2000	Phase II Study of Long-Term Dehydroepiandrosterone for Systemic Lupus Erythematosus		Systemic Lupus Erythematosus	Drug: dehydroepiandrosterone	National Center for Research Resources (NCRR)	Northwestern University	Completed	18 Years	N/A	Female	20	Phase 2	NULL
5	NCT00004795 (ClinicalTrials.gov)	August 1994	24/2/2000	Phase II/III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone in Women With Mild to Moderate Systemic Lupus Erythematosus		Systemic Lupus Erythematosus	Drug: dehydroepiandrosterone	National Center for Research Resources (NCRR)	Northwestern University	Completed	18 Years	N/A	Female	190	Phase 2/Phase 3	NULL

Back to top

53. Sjogren syndrome

---

Clinical trials : 305 /  Drugs : 325 - (DrugBank : 104) / Drug target genes : 58 - Drug target pathways : 188

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00543166 (ClinicalTrials.gov)	February 2003	9/10/2007	Sex Steroids in Sjögren's Syndrome: Effect of Substitution Treatment on Fatigue	Sex Steroids in Sjögren's Syndrome: Effect of Substitution Treatment on Fatigue	Sjogren's Syndrome	Drug: dehydroepiandrosterone	Helsinki University	Göteborg University;Uppsala University	Active, not recruiting	18 Years	80 Years	Both	107	Phase 4	Finland
2	NCT00391924 (ClinicalTrials.gov)	May 2000	24/10/2006	Dehydroepiandrosterone Administration in Women With Systemic Lupus Erythematosus or Primary Sjögren's Syndrome	Fatigue and General Well-Being in Patients With Systemic Lupus Erythematosus or Primary Sjögren's Syndrome: Effects of Dehydroepiandrosterone Administration	Lupus Erythematosus, Systemic;Sjogren's Syndrome	Drug: Dehydroepiandrosterone	UMC Utrecht	University Medical Centre Groningen;Dutch Arthritis Association	Completed	18 Years	N/A	Female	120	Phase 2	Netherlands
3	NCT00001598 (ClinicalTrials.gov)	May 1997	3/11/1999	DHEA Treatment for Sjogren's Syndrome	Dehydroepiandrosterone (DHEA) Treatment for Sjogren's Syndrome	Lacrimal Apparatus Disease;Salivary Gland Disease;Sjogren's Syndrome;Xerostomia	Drug: Dehydroepiandrosterone	National Institute of Dental and Craniofacial Research (NIDCR)	NULL	Completed	N/A	N/A	Female	28	Phase 2	United States

83. Addison disease

---

Clinical trials : 20 /  Drugs : 39 - (DrugBank : 13) / Drug target genes : 6 - Drug target pathways : 18

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00004313 (ClinicalTrials.gov)	August 1995	18/10/1999	Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone Replacement for Primary Adrenal Insufficiency		Addison's Disease	Drug: dehydroepiandrosterone	National Center for Research Resources (NCRR)	University of California, Los Angeles	Completed	18 Years	N/A	Both	40	Phase 3	NULL

96. Crohn disease

---

Clinical trials : 2,442 /  Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00106314 (ClinicalTrials.gov)	January 2005	22/3/2005	An Efficacy and Safety Evaluation of Inflabloc Cap in the Treatment of Patients With Crohn's Disease	A Randomized, Double-Blind, Multi-Center, Dose Response, Efficacy and Safety Evaluation of Inflabloc Cap in the Treatment of Patients With Moderately Active Crohn's Disease	Crohn's Disease	Drug: Dehydroepiandrosterone [DHEA]	Inflabloc Pharmaceuticals	NULL	Completed	18 Years	N/A	Both	75	Phase 2	United States;Canada

113. Muscular dystrophy

---

Clinical trials : 646 /  Drugs : 471 - (DrugBank : 105) / Drug target genes : 59 - Drug target pathways : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00167609 (ClinicalTrials.gov)	November 2004	10/9/2005	Efficacy and Safety of DHEA for Myotonic Dystrophy	Phase 3 Study of Oral Dehydroepiandrosterone (DHEA) in Adults With Myotonic Dystrophy	Myotonic Dystrophy	Drug: dehydroepiandrosterone 100 and 400 mg	University of Versailles	Association Française contre les Myopathies (AFM), Paris;AP-HP	Completed	18 Years	70 Years	Both	75	Phase 2/Phase 3	France

Back to top